Cargando…

A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer

BACKGROUND: Lenvatinib is a multikinase inhibitor approved to treat radioiodine-refractory differentiated thyroid cancer (RR-DTC) at a starting dose of 24 mg/day. This study explored, in a double-blinded fashion, whether a starting dose of 18 mg/day would provide comparable efficacy with reduced tox...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brose, Marcia S, Panaseykin, Yury, Konda, Bhavana, de la Fouchardiere, Christelle, Hughes, Brett G M, Gianoukakis, Andrew G, Joo Park, Young, Romanov, Ilia, Krzyzanowska, Monika K, Leboulleux, Sophie, Binder, Terri A, Dutcus, Corina, Xie, Ran, Taylor, Matthew H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852210/ https://www.ncbi.nlm.nih.gov/pubmed/34664662 http://dx.doi.org/10.1210/clinem/dgab731

Ejemplares similares

Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day
por: Taylor, Matthew H., et al.
Publicado: (2022)

Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer
por: Hayato, Seiichi, et al.
Publicado: (2018)

Prolonged duration of response in lenvatinib responders with thyroid cancer
por: Gianoukakis, Andrew G, et al.
Publicado: (2018)

Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib
por: Taylor, Matthew H., et al.
Publicado: (2021)

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
por: Kiyota, Naomi, et al.
Publicado: (2017)

Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit
por: Wirth, Lori J, et al.
Publicado: (2022)

Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes
por: Haddad, Robert I., et al.
Publicado: (2017)

Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice
por: Capdevila, Jaume, et al.
Publicado: (2023)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
por: Herranz, Urbano Anido
Publicado: (2022)

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
por: Makker, Vicky, et al.
Publicado: (2020)

Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer
por: Robinson, Bruce, et al.
Publicado: (2016)

Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program
por: Balmelli, Catharina, et al.
Publicado: (2018)

A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update
por: Makker, Vicky, et al.
Publicado: (2023)

Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial
por: Kiyota, Naomi, et al.
Publicado: (2022)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
por: Wirth, Lori J., et al.
Publicado: (2021)

Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies
por: Motzer, Robert J., et al.
Publicado: (2022)

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
por: Lorusso, Loredana, et al.
Publicado: (2016)

An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients with Advanced Solid Tumors
por: Shumaker, Robert, et al.
Publicado: (2020)

Myasthenia gravis: MuSK MG, late-onset MG and ocular MG
por: Deymeer, Feza
Publicado: (2020)

Quadrupole Moments of $^{29}$Mg and $^{33}$Mg
por: Yordanov, Deyan Todorov, et al.
Publicado: (2019)

A combined experimental and computational study on the reaction of fluoroarenes with Mg–Mg, Mg–Zn, Mg–Al and Al–Zn bonds
por: Bakewell, Clare, et al.
Publicado: (2018)

Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial
por: Dotinga, Maaike, et al.
Publicado: (2022)

A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer
por: Capdevila, Jaume, et al.
Publicado: (2022)

Lenvatinib-Associated Cervical Artery Dissections in a Patient with Radioiodine-Refractory Metastatic Papillary Thyroid Carcinoma
por: Groden, Phillip J., et al.
Publicado: (2018)

Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review
por: Sheu, Nai-Wei, et al.
Publicado: (2019)

(18)F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib
por: Ahmaddy, Freba, et al.
Publicado: (2021)

A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
por: Zheng, Xiangqian, et al.
Publicado: (2021)

Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine‐refractory differentiated thyroid cancer
por: Martínez‐Trufero, Javier
Publicado: (2022)

Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine‐refractory differentiated thyroid cancer
por: Berciano‐Guerrero, Miguel‐Ángel
Publicado: (2022)

SAT-039 The Short-Term Effect of Multiple Kinase Inhibitor (Lenvatinib) on Spermatogenesis in Mice
por: Lue, Yanhe, et al.
Publicado: (2020)

Evaluation of Mg Compounds as Coating Materials in Mg Batteries
por: Chen, Tina, et al.
Publicado: (2019)

Experimentally Observed Nucleation and Growth Behavior of Mg/MgH(2) during De/Hydrogenation of MgH(2)/Mg: A Review
por: Lyu, Jinzhe, et al.
Publicado: (2022)

Analgesic effect of oral paracetamol 1000 mg/ibuprofen 400 mg, paracetamol 1000 mg/codeine 60 mg, paracetamol 1000 mg/ibuprofen 400 mg/codeine 60 mg, or placebo on acute postoperative pain: a single-dose, randomized, and double-blind study
por: Lyngstad, Gaute, et al.
Publicado: (2023)

The reactive Mg-liquid infiltration to obtain long superconducting MgB$_{2}$ cables
por: Giunchi, G
Publicado: (2009)

The mass of $^{22}$Mg
por: Mukherjee, M, et al.
Publicado: (2004)

The Influence of MgH(2) on the Assessment of Electrochemical Data to Predict the Degradation Rate of Mg and Mg Alloys
por: Mueller, Wolf-Dieter, et al.
Publicado: (2014)

Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer
por: Kiyota, Naomi, et al.
Publicado: (2015)

Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma – A Real-World Experience
por: Jiang, He-Jiun, et al.
Publicado: (2021)

Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
por: Suzuki, Chiaki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lrm06mf338jlumqu5iagjm2eih